Oruka Therapeutics, Inc.
ORKA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.37 | -0.30 | 0.08 | 0.13 |
| FCF Yield | -2.56% | -4.90% | -4.88% | -5.79% |
| EV / EBITDA | -25.05 | -16.71 | -16.44 | -7.08 |
| Quality | ||||
| ROIC | -6.98% | -8.22% | -6.86% | -10.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.94 | 0.99 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 6.38% | -11.00% | -10.86% | 46.23% |
| Safety | ||||
| Net Debt / EBITDA | 2.95 | 2.57 | 3.94 | 1.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |